Enveric Reconciled Depreciation from 2010 to 2024
| ENVB Stock | USD 0.33 0.01 2.94% |
Reconciled Depreciation | First Reported 1996-09-30 | Previous Quarter 85.4 K | Current Value 84.8 K | Quarterly Volatility 343.3 K |
Check Enveric Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Enveric Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 327, Interest Expense of 3.5 K or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.33, Dividend Yield of 475.8 K or PTB Ratio of 1.36. Enveric financial statements analysis is a perfect complement when working with Enveric Biosciences Valuation or Volatility modules.
Enveric | Reconciled Depreciation |
Latest Enveric Biosciences' Reconciled Depreciation Growth Pattern
Below is the plot of the Reconciled Depreciation of Enveric Biosciences over the last few years. It is Enveric Biosciences' Reconciled Depreciation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Enveric Biosciences' overall financial position and show how it may be relating to other accounts over time.
| Reconciled Depreciation | 10 Years Trend |
|
Reconciled Depreciation |
| Timeline |
Enveric Reconciled Depreciation Regression Statistics
| Arithmetic Mean | 2,196,761 | |
| Geometric Mean | 1,500,629 | |
| Coefficient Of Variation | 60.80 | |
| Mean Deviation | 1,191,851 | |
| Median | 3,217,191 | |
| Standard Deviation | 1,335,601 | |
| Sample Variance | 1.8T | |
| Range | 3.1M | |
| R-Value | (0.86) | |
| Mean Square Error | 491.1B | |
| R-Squared | 0.74 | |
| Significance | 0.000035 | |
| Slope | (257,662) | |
| Total Sum of Squares | 25T |
Enveric Reconciled Depreciation History
About Enveric Biosciences Financial Statements
Enveric Biosciences stakeholders use historical fundamental indicators, such as Enveric Biosciences' Reconciled Depreciation, to determine how well the company is positioned to perform in the future. Although Enveric Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Enveric Biosciences' assets and liabilities are reflected in the revenues and expenses on Enveric Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Enveric Biosciences. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Reconciled Depreciation | 414 K | 393.3 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Enveric Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enveric Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enveric Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enveric Biosciences Stock:Check out the analysis of Enveric Biosciences Correlation against competitors. For information on how to trade Enveric Stock refer to our How to Trade Enveric Stock guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enveric Biosciences. If investors know Enveric will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enveric Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.42) | Revenue Per Share 37.678 | Quarterly Revenue Growth (0.07) | Return On Assets (0.81) | Return On Equity (2.06) |
The market value of Enveric Biosciences is measured differently than its book value, which is the value of Enveric that is recorded on the company's balance sheet. Investors also form their own opinion of Enveric Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Enveric Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enveric Biosciences' market value can be influenced by many factors that don't directly affect Enveric Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enveric Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enveric Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enveric Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.